Cilostazol inhibits platelet–leukocyte interaction by suppression of platelet activation

References

• Kuijper P H, Gallardo Torres H I, van der Linden J A, Lammers J W, Sixma J J, Koenderman L, Zwaginga J J. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endo-thelium under flow conditions. Blood 1996; 87: 3271–81.
   PubMedGoogle Scholar
• Nwariaku F E, Mileski W J, Lightfoot E Jr, Sikes P J, Lipsky P E. Alterations in leukocyte adhesion molecule expression after burn injury. J Trauma 1995; 39: 285–88.
   PubMedGoogle Scholar
• Kirchhofer D, Riederer M A, Baumgartner H R. Specific accumulation of circulating monocytes and polymorphonu- clear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89: 1270–78.
   PubMed Web of Science ®Google Scholar
• Sarma J, Laan C A, Alam S, Jha A, Fox K A, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166–71.
   PubMed Web of Science ®Google Scholar
• Rinder H M, Bonan J L, Rinder C S, Ault K A, Smith B R. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991; 78: 1730–37.
   PubMed Web of Science ®Google Scholar
• Li N, Hu H, Lindqvist M, Wikstrom-Jonsson E, Goodall A H, Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702–8.
   PubMed Web of Science ®Google Scholar
• Maugeri N, Evangelista V, Celardo A, Dell’Elba G, Martelli N, Piccardoni P, de Gaetano G, Cerletti C. leukocyte-platelet interaction: role of in throm-boxane B2 and leukotriene C4 cooperative synthesis. Thromb Haemost 1994; 72: 450–56.
   PubMed Web of Science ®Google Scholar
• Nagata K, Tsuji T, Todoroki N, Katagiri Y, Tanoue K, Yamazaki H, Hanai N, Irimura T. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol 1993; 151: 3267–73.
   PubMed Web of Science ®Google Scholar
• Freedman J E, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130–32.
   PubMedGoogle Scholar
• Grau A J, Sigmund R, Hacke W. Modification of platelet aggregation by leukocytes in acute ischemic stroke. Stroke 1994; 25: 2149–52.
   PubMedGoogle Scholar
• Mehta J L, Nicolini F A, Donnelly W H, Nichols W W. Platelet-leukocyte-endothelial interactions in coronary artery disease. Am J Cardiol 1992; 69: 8B–13B.
   Google Scholar
• Evangelista V, Manarini S, Sideri R, Rotondo S, Martelli N, Piccoli A, Totani L, Piccardoni P, Vestweber D, de Gaetano G, Cerletti C. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation- depen- dent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876–85.
   PubMed Web of Science ®Google Scholar
• Stenberg P E, McEver R P, Shuman M A, Jacques Y V, Bainton D F. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880–86
   PubMedGoogle Scholar
• Hamburger S A, McEver R P. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550–54.
   PubMed Web of Science ®Google Scholar
• Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, Mayer H, Grau A J. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570–4.
   PubMed Web of Science ®Google Scholar
• Gawaz M, Neumann F J, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of anti- thrombotic therapy. Circulation 1996; 94: 279–85.
   PubMed Web of Science ®Google Scholar
• Minamino T, Kitakaze M, Sanada S, Asanuama H, Kurotobi T, Koretsune Y, Fukunami M, Kuzuya T, Hoki N, Hori M. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998; 98: 1721–7.
   PubMed Web of Science ®Google Scholar
• Nurden A T, Macchi L, Bihour C, Durrieu C, Besse P, Nurden P. Markers of platelet activation in coronary heart disease patients. Eur J Clin Invest 1994; 24 (Suppl 1): 42–5.
   Google Scholar
• Kamiya T, Sakaguchi S. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities. Arzneimittelforschung 1985; 35: 1201–3.
   PubMedGoogle Scholar
• Dawson D L, Cutler B S, Meissner M H, Strandness D E Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospec- tive, double-blind trial. Circulation 1998; 98: 678–86.
   PubMedGoogle Scholar
• Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary preven-tion of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147–57.
   PubMedGoogle Scholar
• Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35: 1144–9.
   PubMed Web of Science ®Google Scholar
• Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000; 59: 347–56.
   PubMed Web of Science ®Google Scholar
• Inoue T, Sohma R, Morooka S. Cilostazol inhibits the expression of activation-dependent membrane surface glyco- protein on the surface of platelets stimulated in vitro. Thromb Res 1999; 93: 137–43.
   PubMed Web of Science ®Google Scholar
• Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res 2001; 101: 445–53.
   PubMedGoogle Scholar
• The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–9.
   PubMed Web of Science ®Google Scholar
• Grynkiewicz G, Poenie M, Tsien R Y. A new generation of Ca2þ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440–50.
   PubMed Web of Science ®Google Scholar
• Cobbold P H, Rink T J. Fluorescence and bioluminescence measurement of cytoplasmic free calcium. Biochem J 1987; 248: 313–28.
   PubMedGoogle Scholar
• Simon D I, Chen Z, Xu H, Li C Q, Dong J, McIntire L V, Ballantyne C M, Zhang L, Furman M I, Berndt M C, Lopez J A. Platelet glycoprotein Iba is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193–204.
   PubMedGoogle Scholar
• Weber C, Springer T A. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085–93.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Marukawa K, Okumura H, Adachi T, Tani T, Kimura Y. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses. Thromb Res 1999; 95: 19–29.
   Google Scholar
• Sudo T, Ito H, Kimura Y. Phosphorylation of the vasodilator- stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets 2003; 14: 381–390.
   PubMed Web of Science ®Google Scholar
• Harbeck B, Huttelmaier S, Schluter K, Jockusch B M, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 2000; 275: 30817–25.
   PubMed Web of Science ®Google Scholar
• Horstrup K, Jablonka B, Honig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator- stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994; 225: 21–7.
   Google Scholar
• Konstantopoulos K, Neelamegham S, Burns A R, Hentzen E, Kansas G S, Snapp K R, Berg E L, Hellums J D, Smith C W, McIntire L V, Simon S I. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation 1998; 98: 873–82.
   Google Scholar
• Libersan D, Rousseau G, Merhi Y. Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets. Thromb Haemost 2003; 89: 310–7.
   PubMed Web of Science ®Google Scholar
• Michelson A D, Barnard M R, Krueger L A, Valeri C R, Furman M I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533–7.
   PubMed Web of Science ®Google Scholar
• Sarma J, Laan C A, Alam S, Jha A, Fox K A, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166–71.
   PubMed Web of Science ®Google Scholar
• Taylor M L, Ilton M K, Misso N L, Watkins D N, Hung J, Thompson P J. The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutro- phils. Br J Clin Pharmacol 1998; 46: 139–45.
   PubMedGoogle Scholar
• Pearson D A, Paglieroni T G, Rein D, Wun T, Schramm D D, Wang J F, Holt R R, Gosselin R, Schmitz H H, Keen C L. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Thromb Res 2002; 106: 191–7.
   PubMedGoogle Scholar
• Caron A, Theoret J F, Mousa S A, Merhi Y. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet acti- vation, and binding to neutrophils. J Cardiovasc Pharmacol 2002; 40: 296–306.
   PubMed Web of Science ®Google Scholar
• Barlage S, Wimmer A, Pfeiffer A, Rothe G, Schmitz G. MK- 383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor. Platelets 2002; 13: 133–40.
   PubMed Web of Science ®Google Scholar
• Dickfeld T, Ruf A, Pogatsa-Murray G, Muller I, Engelmann B, Taubitz W, Fischer J, Meier O, Gawaz M. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thromb Res 2001; 101: 53–64.
   PubMed Web of Science ®Google Scholar
• Kikura M, Kazama T, Ikeda T, Sato S. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood. Platelets 2000; 11: 446–58.
   PubMedGoogle Scholar